Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NNMT | P40261 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674216 | 0.86 | NPSR1 (0.65) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL10915987 | 0.85 | NPSR1 (0.59) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL3062156 | 0.84 | NPSR1 (0.58) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL677578 | 0.83 | NPSR1 (0.61) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL16673895 | 0.83 | NPSR1 (0.61) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL9811156 | 0.83 | L3MBTL1 (0.61) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL5430523 | 0.83 | MAPT (0.63) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL3072623 | 0.81 | HSP90AA1 (0.64) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL16673898 | 0.81 | NPSR1 (0.59) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 | |
| SCHEMBL13934018 | 0.81 | NPSR1 (0.84) | L3MBTL1NPSR1MAPTNNMTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295211-A1 | METHODS OF PRODUCING CRYSTALLINE BETA NICOTINAMIDE RIBOSIDE TRIACETATE CHLORIDE | ChromaDex Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-2156182-B1 | DETECTION OF AN ANALYTE IN A SAMPLE OF HEMOLYZED WHOLE BLOOD | ROCHE DIAGNOSTICS GMBH (DE) | 2010-10-06 | — | — | EP | disclosed |
| US-4631339-A | 1,3,5-triazepinones | ELI LILLY AND COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4514564-A | 7β-(2'-(1\",3\",5\"-Triazepin-4\"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4436912-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4430499-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295211-A1 | METHODS OF PRODUCING CRYSTALLINE BETA NICOTINAMIDE RIBOSIDE TRIACETATE CHLORIDE | NAMPT, NADK, ADH1B | L3MBTL1 4005/4885NPSR1 3392/4885MAPT 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.